Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

N/A
4(80.0%)
Early Phase 1
1(20.0%)
5Total
N/A(4)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05742906Not ApplicableRecruiting

CorMatrix Cor TRICUSPID ECM Valve Replacement - Pivotal Study

Role: lead

NCT02397668Not ApplicableRecruiting

CorMatrix Cor TRICUSPID ECM Valve Replacement Study

Role: lead

NCT01535807Not ApplicableTerminated

CorMatrix ECM Study: To Identify Inflammatory Markers Following CABG With/Without ECM

Role: collaborator

NCT02887768Early Phase 1Completed

Epicardial Infarct Repair Using CorMatrix®-ECM: Clinical Feasibility Study

Role: collaborator

NCT02139189Not ApplicableCompleted

Restore Myocardial Function With CorMatrix® ECM® Particulate (P-ECM)

Role: lead

All 5 trials loaded